Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Leuk Lymphoma

Retrieve available abstracts of 284 articles:
HTML format

Single Articles

    November 2022
  1. MULLIGAN SP, Opat S, Cheah CY, Kuss B, et al
    Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program.
    Leuk Lymphoma. 2022 Nov 24:1-7. doi: 10.1080/10428194.2022.2148220.
    PubMed     Abstract available

  2. ECTOR GICG, Geelen IGP, Dinmohamed AG, Hoogendoorn M, et al
    Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands.
    Leuk Lymphoma. 2022 Nov 11:1-9. doi: 10.1080/10428194.2022.2142055.
    PubMed     Abstract available

  3. FENG X, Zheng Y, Xu J
    Morphology and clinical characteristics of a case of FIP1L1-RARA fusion-associated variant acute promyelocytic leukemia.
    Leuk Lymphoma. 2022 Nov 9:1-4. doi: 10.1080/10428194.2022.2142052.

  4. CHEN WONGWORAWAT Y, Eskandari G, Gaikwad A, Marcogliese AN, et al
    Frequent detection of CBFA2T3::GLIS2 fusion and RAM-phenotype in pediatric non-Down syndrome acute megakaryoblastic leukemia: a possible novel relationship with aberrant cytoplasmic CD3 expression.
    Leuk Lymphoma. 2022 Nov 8:1-6. doi: 10.1080/10428194.2022.2140285.

  5. DOUKAS PG, Cascino GJ, Meng Z, Baldridge AS, et al
    External validation of a heart failure risk score in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2022 Nov 4:1-9. doi: 10.1080/10428194.2022.2140289.
    PubMed     Abstract available

  6. BALL S, Loghavi S, Zeidan AM
    TP53-altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs.
    Leuk Lymphoma. 2022 Nov 2:1-11. doi: 10.1080/10428194.2022.2136969.
    PubMed     Abstract available

  7. AHMED M, Pollyea DA
    Lower intensity regimens for acute myeloid leukemia: opportunities and challenges.
    Leuk Lymphoma. 2022 Nov 2:1-5. doi: 10.1080/10428194.2022.2136960.
    PubMed     Abstract available

  8. ZHANG X, Tu Y, Shen J, Feng Y, et al
    Effectiveness and safety of leukapheresis in hyperleukocytic leukemias: a retrospective multicenter study.
    Leuk Lymphoma. 2022;63:2636-2644.
    PubMed     Abstract available

  9. CHANDHOK NS, Sekeres MA
    What constitutes meaningful improvement in myelodysplastic syndromes?
    Leuk Lymphoma. 2022;63:2528-2535.
    PubMed     Abstract available

  10. CHEN Y, Buhlinger K, Perissinotti AJ, Schepers AJ, et al
    Solving coagulation conundrums: comparing prophylaxis strategies in adult patients receiving PEG-asparaginase.
    Leuk Lymphoma. 2022;63:2663-2670.
    PubMed     Abstract available

    October 2022
  11. BEWERSDORF JP, Shallis RM, Derkach A, Goldberg AD, et al
    Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors.
    Leuk Lymphoma. 2022 Oct 26:1-9. doi: 10.1080/10428194.2022.2136952.
    PubMed     Abstract available

  12. SHAHZAD M, Chaudhary SG, Tariq E, Mushtaq AH, et al
    Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review.
    Leuk Lymphoma. 2022 Oct 25:1-10. doi: 10.1080/10428194.2022.2136947.
    PubMed     Abstract available

  13. HELFGOTT DC, Racine-Brzostek S, Short KJ, Zhao Z, et al
    Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Leuk Lymphoma. 2022 Oct 25:1-9. doi: 10.1080/10428194.2022.2131414.
    PubMed     Abstract available

  14. GALLON R, Phelps R, Betts L, Hayes C, et al
    Detection of constitutional mismatch repair deficiency in children and adolescents with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Oct 22:1-4. doi: 10.1080/10428194.2022.2131412.

  15. WANG KY, Shah P, Skavla B, Fayaaz F, et al
    Vaccination efficacy in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Oct 21:1-15. doi: 10.1080/10428194.2022.2133538.
    PubMed     Abstract available

  16. OTHUS M, Thomas I, Wang X, Ariti C, et al
    Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.
    Leuk Lymphoma. 2022 Oct 13:1-3. doi: 10.1080/10428194.2022.2131416.

  17. OYAMA T, Matsuda K, Honda A, Yasunaga M, et al
    Long-term follow-up of central nervous system relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
    Leuk Lymphoma. 2022 Oct 12:1-4. doi: 10.1080/10428194.2022.2131421.

  18. AQIL B, Gao J, Rahn HR, Sukhanova M, et al
    Non-leukemic presentation of acute promyelocytic leukemia as a testicular mass with associated non-canonical FLT3 mutation.
    Leuk Lymphoma. 2022 Oct 10:1-4. doi: 10.1080/10428194.2022.2131425.

  19. PAULUS A, Malavasi F, Chanan-Khan A
    CD38 as a multifaceted immunotherapeutic target in CLL.
    Leuk Lymphoma. 2022;63:2265-2275.
    PubMed     Abstract available

  20. USTUN C, Warlick E, Nathan S, Burns LJ, et al
    Transplantation provides superior survival high risk myeloid malignancies in older patients.
    Leuk Lymphoma. 2022;63:2494-2498.

  21. ENGVALL M, Karlsson Y, Kuchinskaya E, Jornegren A, et al
    Familial platelet disorder due to germline exonic deletions in RUNX1: a diagnostic challenge with distinct alterations of the transcript isoform equilibrium.
    Leuk Lymphoma. 2022;63:2311-2320.
    PubMed     Abstract available

    September 2022
  22. ISHITSUKA K, Yoshizawa Y, Nishikii H, Kusakabe M, et al
    Novel translocation of POGZ/STK11 in de novo mast cell leukemia with KIT D816H mutation.
    Leuk Lymphoma. 2022 Sep 20:1-5. doi: 10.1080/10428194.2022.2123235.

  23. SIMON F, Giza A, Robrecht S, Fink AM, et al
    Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older.
    Leuk Lymphoma. 2022 Sep 18:1-8. doi: 10.1080/10428194.2022.2123223.
    PubMed     Abstract available

  24. SHAHZAD M, Tariq E, Chaudhary SG, Anwar I, et al
    Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.
    Leuk Lymphoma. 2022 Sep 15:1-9. doi: 10.1080/10428194.2022.2123228.
    PubMed     Abstract available

  25. LIU X, Zou Y, Zhang L, Zhang Y, et al
    Characteristics and prognosis of children with recurrent T-cell acute lymphoblastic leukemia: a long-term follow-up report in China.
    Leuk Lymphoma. 2022 Sep 15:1-13. doi: 10.1080/10428194.2022.2123224.
    PubMed     Abstract available

  26. ZAINALDIN C, Arora S, Bathini S, Gupta U, et al
    Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents.
    Leuk Lymphoma. 2022 Sep 15:1-4. doi: 10.1080/10428194.2022.2113530.

  27. BEHDAD A, Schipma MJ, Ma S, Chen YH, et al
    Distinct immune-response profile of Richter transformation chronic lymphocytic leukemia (CLL), defined by high expression of PD1, LAG3, TIM3 and IL-10.
    Leuk Lymphoma. 2022 Sep 14:1-5. doi: 10.1080/10428194.2022.2123236.

  28. MUKAE J, Sadato D, Toya T, Watanabe S, et al
    Labile CD22 and CD19 expression in a case of Philadelphia chromosome-like acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Sep 14:1-4. doi: 10.1080/10428194.2022.2116936.

  29. EDAHIRO T, Ureshino H, Chishaki R, Fujino K, et al
    Successful combination treatment with azacitidine and venetoclax for a patient with acute myeloid leukemia undergoing hemodialysis.
    Leuk Lymphoma. 2022 Sep 13:1-2. doi: 10.1080/10428194.2022.2123230.

  30. CAI Z, Liu Y, Tang B, Wu Z, et al
    Dynamics of minimal residual disease defines a novel risk-classification and the role of allo-HSCT in adult Ph-negative B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Sep 13:1-10. doi: 10.1080/10428194.2022.2115841.
    PubMed     Abstract available

  31. BALL BJ, Arslan S, Koller P, Ngo D, et al
    Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).
    Leuk Lymphoma. 2022 Sep 10:1-5. doi: 10.1080/10428194.2022.2116934.

  32. PATIL P, Toprak UH, Seufert J, Braun T, et al
    Exploration of whole genome and transcriptome sequencing data lacks evidence for oncogenic viral elements to drive the pathogenesis of T-cell prolymphocytic leukemia.
    Leuk Lymphoma. 2022 Sep 9:1-4. doi: 10.1080/10428194.2022.2116933.

  33. ANDRITSOS LA, Anghelina M, Neal J, Blachly JS, et al
    Development of a distributed international patient data registry for hairy cell leukemia.
    Leuk Lymphoma. 2022 Sep 7:1-11. doi: 10.1080/10428194.2022.2109157.
    PubMed     Abstract available

  34. NAGATA A, Otsuka Y, Konuma R, Adachi H, et al
    Weight-adjusted urinary creatinine excretion predicts transplant outcomes in adult patients with acute myeloid leukemia in complete remission.
    Leuk Lymphoma. 2022 Sep 6:1-11. doi: 10.1080/10428194.2022.2109334.
    PubMed     Abstract available

  35. TIBOUT P, Ledjiar O, Athale U, Rayar M, et al
    Prognostic factors and outcomes of infant acute lymphoblastic leukemia (ALL), hypodiploid ALL, and mixed-phenotype acute leukemia (MPAL) in Canada: a report from CYP-C.
    Leuk Lymphoma. 2022 Sep 6:1-9. doi: 10.1080/10428194.2022.2118536.
    PubMed     Abstract available

  36. WEI Y, Zheng H, Lockyer PP, Darbaniyan F, et al
    MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2022 Sep 5:1-11. doi: 10.1080/10428194.2022.2116932.
    PubMed     Abstract available

  37. DURINIKOVA A, Folta A, Pardy F, Svaton J, et al
    Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients.
    Leuk Lymphoma. 2022 Sep 1:1-4. doi: 10.1080/10428194.2022.2116931.

  38. GAGNON MF, Smadbeck JB, Sharma N, Blackburn PR, et al
    Apparent coexistence of ETV6::RUNX1 and KMT2A::MLLT3 fusions due to a nonproductive KMT2A rearrangement in B-ALL.
    Leuk Lymphoma. 2022;63:2243-2246.

  39. MCCAY J, Gribben JG
    The role of BTK inhibitors on the tumor microenvironment in CLL.
    Leuk Lymphoma. 2022;63:2023-2032.
    PubMed     Abstract available

    August 2022
  40. COSTA DFD, Filiu-Braga LDC, Silva-Carvalho AE, Schiavinato JL, et al
    Transcriptional deregulation of LSD1 and LSD2 is associated with cytogenetic risk in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Aug 25:1-5. doi: 10.1080/10428194.2022.2116935.

  41. LALAYANNI C, Demosthenous C, Iskas M, Kelaidi C, et al
    Adolescents and young adults (AYA) with acute myeloid leukemia (AML): real-world long-term results and age-specific outcomes.
    Leuk Lymphoma. 2022 Aug 24:1-10. doi: 10.1080/10428194.2022.2113527.
    PubMed     Abstract available

  42. NAMJOSHI NS, Keegan THM, Li QC, Chung JH, et al
    Treatment-related toxicities associated with hospitalization in children, adolescents, and young adults with acute lymphoblastic leukemia: population level analysis.
    Leuk Lymphoma. 2022 Aug 23:1-9. doi: 10.1080/10428194.2022.2113533.
    PubMed     Abstract available

  43. ZAK T, Gao J, Behdad A, Mehta J, et al
    Clinicopathologic and genetic evaluation of B-lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21) in adult patients.
    Leuk Lymphoma. 2022 Aug 22:1-8. doi: 10.1080/10428194.2022.2113524.
    PubMed     Abstract available

  44. SUDUTAN T, Erbilgin Y, Hatirnaz Ng O, Karaman S, et al
    Zinc finger protein 384 (ZNF384) impact on childhood mixed phenotype acute leukemia and B-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Aug 3:1-9. doi: 10.1080/10428194.2022.2095630.
    PubMed     Abstract available

  45. PERAGINE N, De Propris MS, Intoppa S, Milani ML, et al
    Early CD49d downmodulation in chronic lymphocytic leukemia patients treated front-line with ibrutinib plus rituximab predicts long-term response.
    Leuk Lymphoma. 2022 Aug 1:1-5. doi: 10.1080/10428194.2022.2105324.

  46. TESTI AM, Al-Jadiry MF, Ghali HH, Fadhil SA, et al
    Childhood acute promyelocytic leukemia in a pediatric cancer referral center in Baghdad, Iraq. Improved results with ATRA extended consolidation.
    Leuk Lymphoma. 2022 Aug 1:1-8. doi: 10.1080/10428194.2022.2105328.
    PubMed     Abstract available

    Optimal dosing of cytarabine in childhood acute myeloid leukemia: do we have the answer yet?
    Leuk Lymphoma. 2022 Aug 1:1-3. doi: 10.1080/10428194.2022.2105327.

  48. BASSIG BA, Hu W, Morton LM, Ji BT, et al
    Incidence of myeloid malignancies by subtype in Hong Kong and comparisons with Asian and white men and women in the United States.
    Leuk Lymphoma. 2022;63:1917-1924.
    PubMed     Abstract available

  49. MACARON W, Sargsyan Z, Short NJ
    Hyperleukocytosis and leukostasis in acute and chronic leukemias.
    Leuk Lymphoma. 2022;63:1780-1791.
    PubMed     Abstract available

  50. CHEN EC, Liu Y, Harris CE, Winer ES, et al
    Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax.
    Leuk Lymphoma. 2022;63:1934-1941.
    PubMed     Abstract available

  51. COZAD M, Stump SE, Buhlinger K, Collins J 4th, et al
    Evaluation of an interdisciplinary venetoclax initiation process in minimizing risk of tumor lysis syndrome.
    Leuk Lymphoma. 2022;63:1831-1838.
    PubMed     Abstract available

    July 2022
  52. DHARIA P, Swartz MD, Bernhardt MB, Chen H, et al
    Clinical and demographic factors contributing to asparaginase-associated toxicities in children with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Jul 27:1-7. doi: 10.1080/10428194.2022.2102621.
    PubMed     Abstract available

  53. KUSS B, Nagarajan C, Hsieh WS, Cheah CY, et al
    Practical management of chronic lymphocytic leukemia with acalabrutinib.
    Leuk Lymphoma. 2022 Jul 19:1-10. doi: 10.1080/10428194.2022.2098289.
    PubMed     Abstract available

  54. DAVER N, Jonas BA, Medeiros BC, Patil U, et al
    Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2022 Jul 14:1-4. doi: 10.1080/10428194.2022.2092853.

  55. YAN W, Fan H, Xu J, Liu J, et al
    The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria.
    Leuk Lymphoma. 2022 Jul 12:1-10. doi: 10.1080/10428194.2022.2098290.
    PubMed     Abstract available

  56. KLINGLER F, Alsdorf WH, Ghandili S, Wolschke C, et al
    Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine.
    Leuk Lymphoma. 2022 Jul 5:1-7. doi: 10.1080/10428194.2022.2092855.
    PubMed     Abstract available

    June 2022
  57. XU Z, Yin J, Sun Q, Hu J, et al
    The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation.
    Leuk Lymphoma. 2022 Jun 25:1-11. doi: 10.1080/10428194.2022.2090549.
    PubMed     Abstract available

  58. XU GF, Liu LM, Wang M, Zhang ZB, et al
    Treatments of Ph-like acute lymphoblastic leukemia: a real-world retrospective analysis from a single large center in China.
    Leuk Lymphoma. 2022 Jun 24:1-11. doi: 10.1080/10428194.2022.2090550.
    PubMed     Abstract available

  59. RAA DGT, van der Straten L, van Gelder M, Kersting S, et al
    Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.
    Leuk Lymphoma. 2022 Jun 23:1-14. doi: 10.1080/10428194.2022.2084731.
    PubMed     Abstract available

  60. DHAKAL P, Joshi U, Lyden E, Pyakuryal A, et al
    Association of insurance types and outcomes in acute promyelocytic leukemia.
    Leuk Lymphoma. 2022 Jun 23:1-9. doi: 10.1080/10428194.2022.2090554.
    PubMed     Abstract available

  61. ZONG L, Xie J, Kong J, Bao X, et al
    Lineage switch from acute myeloid leukemia to acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Jun 23:1-3. doi: 10.1080/10428194.2022.2064984.

  62. SERPENTI F, Sciume M, Galassi G, Saporiti G, et al
    Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse.
    Leuk Lymphoma. 2022 Jun 22:1-4. doi: 10.1080/10428194.2022.2090553.

  63. NGO D, Otoukesh S, Stein AS, Forman S, et al
    The safety of concurrent intrathecal chemotherapy during blinatumomab in adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Jun 21:1-3. doi: 10.1080/10428194.2022.2090555.

  64. TEDJASEPUTRA A, Kuzich JA, Thiagarajah N, Teh TC, et al
    Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic.
    Leuk Lymphoma. 2022 Jun 21:1-4. doi: 10.1080/10428194.2022.2087065.

  65. KOHN M, Alsuliman T, Lamure S, Cheminant M, et al
    Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak.
    Leuk Lymphoma. 2022 Jun 18:1-5. doi: 10.1080/10428194.2022.2086249.

  66. SYMES E, Wang P, Lager AM, Bishop MR, et al
    TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression.
    Leuk Lymphoma. 2022 Jun 18:1-4. doi: 10.1080/10428194.2022.2087070.

  67. MOLICA S, Allsup DJ, Polliack A
    Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Jun 15:1-3. doi: 10.1080/10428194.2022.2087072.

  68. YU G, Lu W, Chen X, Li Y, et al
    Single-cell RNA sequencing to explore composition of peripheral blood NK cells in patients with chronic myeloid leukemia in treatment-free remission.
    Leuk Lymphoma. 2022 Jun 11:1-12. doi: 10.1080/10428194.2022.2086243.
    PubMed     Abstract available

  69. LYU X, Li T, Zhu D, Cheng Y, et al
    Whole-genome sequencing as an alternative to analyze copy number abnormalities in acute myeloid leukemia and myelodysplastic syndrome.
    Leuk Lymphoma. 2022 Jun 11:1-10. doi: 10.1080/10428194.2022.2080821.
    PubMed     Abstract available

  70. SABURI M, Sakata M, Takata H, Miyazaki Y, et al
    Poor clinical outcome of elderly patients with primary plasma cell leukemia treated with novel agents: real-world experience.
    Leuk Lymphoma. 2022 Jun 10:1-5. doi: 10.1080/10428194.2022.2086250.

  71. XU J, Hao Z, Chen X, Hong M, et al
    The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing.
    Leuk Lymphoma. 2022 Jun 2:1-9. doi: 10.1080/10428194.2022.2081323.
    PubMed     Abstract available

  72. GADAUD N, Leroy H, Berard E, Tavitian S, et al
    Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study.
    Leuk Lymphoma. 2022;63:1398-1406.
    PubMed     Abstract available

  73. MATUTES E, Polliack A
    Is ibrutinib the gold standard for therapy - naive elderly patients with CLL?
    Leuk Lymphoma. 2022;63:1265-1266.

  74. TAHIR F, Sy J, Reddel S, Trotman J, et al
    Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia.
    Leuk Lymphoma. 2022;63:1464-1468.
    PubMed     Abstract available

  75. SHARPLIN KM, Marks DI
    The treatment landscape for Relapsed Refractory B Acute Lymphoblastic Leukaemia (ALL).
    Leuk Lymphoma. 2022;63:1292-1301.
    PubMed     Abstract available

  76. BALL S, Komrokji RS, Sallman DA
    Prognostic scoring systems and risk stratification in myelodysplastic syndrome: focus on integration of molecular profile.
    Leuk Lymphoma. 2022;63:1281-1291.
    PubMed     Abstract available

    May 2022
  77. MAENG CV, Christiansen CF, Liu KD, Kamper P, et al
    Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort study.
    Leuk Lymphoma. 2022 May 18:1-11. doi: 10.1080/10428194.2022.2074984.
    PubMed     Abstract available

  78. MACHHERNDL-SPANDL S, Vockenhuber T, Binder M, Weltermann A, et al
    Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2022 May 13:1-6. doi: 10.1080/10428194.2022.2068006.
    PubMed     Abstract available

  79. LI Z, Peng L, Li Y, Zhang J, et al
    Lower tumor burden is associated with better cognitive function in patients with chronic phase chronic myeloid leukemia.
    Leuk Lymphoma. 2022 May 11:1-12. doi: 10.1080/10428194.2022.2070912.
    PubMed     Abstract available

  80. ASOUBAR S, Esfahani A, Vahedi A, Mohammadi SM, et al
    Responsible enzymes for metabolizing vitamin D in patients with acute leukemia and the relationship with treatment outcomes: a case-control study.
    Leuk Lymphoma. 2022 May 4:1-7. doi: 10.1080/10428194.2022.2056174.
    PubMed     Abstract available

  81. EVANS MG, Shestakova A, Haghighi N, Zhao X, et al
    Rare case of leptomeningeal small lymphocytic lymphoma with TP53 mutation detected by deep next-generation sequencing.
    Leuk Lymphoma. 2022 May 3:1-5. doi: 10.1080/10428194.2022.2070911.
    PubMed     Abstract available

  82. SZCZEPANEK E, Chukwu O, Kaminska M, Wysoglad H, et al
    Long-term outcomes of patients with Chronic Myeloid Leukemia who commenced treatment with imatinib: a 20-year single-centre experience.
    Leuk Lymphoma. 2022 May 2:1-11. doi: 10.1080/10428194.2022.2068000.
    PubMed     Abstract available

  83. PREBET T, Goldberg AD, Jurcic JG, Khaled S, et al
    A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia.
    Leuk Lymphoma. 2022 May 1:1-9. doi: 10.1080/10428194.2022.2057484.
    PubMed     Abstract available

  84. QIN T, Cheng Y, Wang X
    RNA-binding proteins as drivers of AML and novel therapeutic targets.
    Leuk Lymphoma. 2022;63:1045-1057.
    PubMed     Abstract available

  85. SAUMELL S, Fernandez-Serrano M, Mesa A, Lopez-Cadenas F, et al
    Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes.
    Leuk Lymphoma. 2022;63:1227-1235.
    PubMed     Abstract available

  86. LI J, Liao D, Wang F, Wang Z, et al
    RIPK1 inhibition enhances the therapeutic efficacy of chidamide in FLT3-ITD positive AML, both in vitro and in vivo.
    Leuk Lymphoma. 2022;63:1167-1179.
    PubMed     Abstract available

    April 2022
  87. QI D, Wang J, Zhao Y, Yang Y, et al
    JMJD1C-regulated lipid synthesis contributes to the maintenance of MLL-rearranged acute myeloid leukemia.
    Leuk Lymphoma. 2022 Apr 25:1-12. doi: 10.1080/10428194.2022.2068004.
    PubMed     Abstract available

  88. LI Q, Liang C, Xu X, Zhang C, et al
    CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia.
    Leuk Lymphoma. 2022 Apr 23:1-13. doi: 10.1080/10428194.2022.2064986.
    PubMed     Abstract available

  89. PHAM TM, Quy PN, Amin K, Walker E, et al
    Average lifespan shortened due to Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, and leukemia in Japan, 1990-2015.
    Leuk Lymphoma. 2022 Apr 23:1-10. doi: 10.1080/10428194.2022.2064990.
    PubMed     Abstract available

  90. PETROV D, Timilshina N, Papadopoulos E, Alibhai SMH, et al
    Performance of the frailty index in predicting complete remission, intensive care unit admission, and overall mortality in older and younger patients with acute myeloid leukemia receiving intensive chemotherapy.
    Leuk Lymphoma. 2022 Apr 22:1-8. doi: 10.1080/10428194.2022.2064993.
    PubMed     Abstract available

  91. MEMOLI M, Genthon A, Favale F, Lapusan S, et al
    Prognostic impact of early minimal residual disease combined with complete molecular evaluation in acute myeloid leukemia with mutated NPM1: a single center study.
    Leuk Lymphoma. 2022 Apr 22:1-9. doi: 10.1080/10428194.2022.2064987.
    PubMed     Abstract available

  92. SHORT NJ, Borthakur G, Pemmaraju N, Dinardo CD, et al
    A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia.
    Leuk Lymphoma. 2022 Apr 20:1-10. doi: 10.1080/10428194.2022.2062345.
    PubMed     Abstract available

  93. NAKASE K, Tanaka I, Tawara I, Shiku H, et al
    CD22 expression in acute myeloid leukemia: close correlation with interleukin-2 receptor alpha-chain (CD25) expression and poor prognosis.
    Leuk Lymphoma. 2022 Apr 20:1-3. doi: 10.1080/10428194.2022.2062346.

  94. XUE S, Huang W, Liu F, Zhang Y, et al
    Rapid response to avapritinib of acute myeloid leukemia with t(8;21) and KIT mutation relapse post allo-HSCT.
    Leuk Lymphoma. 2022 Apr 19:1-4. doi: 10.1080/10428194.2022.2064994.

  95. MIRANTI E, Ho DY, Enriquez K, Subramanian AK, et al
    Epidemiology of invasive fungal diseases in adults with newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2022 Apr 12:1-7. doi: 10.1080/10428194.2022.2060504.
    PubMed     Abstract available

  96. MANGAONKAR AA, Patnaik MM
    Role of the bone marrow immune microenvironment in chronic myelomonocytic leukemia pathogenesis: novel mechanisms and insights into clonal propagation.
    Leuk Lymphoma. 2022 Apr 4:1-9. doi: 10.1080/10428194.2022.2056175.
    PubMed     Abstract available

  97. MINDIOLA ROMERO AE, Johnston MA, Giffin JT, Khan WA, et al
    SNP-based chromosomal microarray characterization in a series of pure erythroid leukemia.
    Leuk Lymphoma. 2022 Apr 3:1-4. doi: 10.1080/10428194.2022.2057489.

  98. FERNANDEZ A, Perez-Martinez A, Escudero A, Mirones I, et al
    Infusion of haploidentical NKG2D-CAR-TCD45RA- cells in two pediatric patients with advanced relapsed and refractory acute leukemia was safe but achieved no clinical benefits.
    Leuk Lymphoma. 2022 Apr 3:1-5. doi: 10.1080/10428194.2022.2057490.

  99. HADDAD F, Kantarjian H, Issa GC, Jabbour E, et al
    Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia.
    Leuk Lymphoma. 2022 Apr 1:1-4. doi: 10.1080/10428194.2022.2045599.

  100. MIYAMOTO T, Sanford D, Tomuleasa C, Hsiao HH, et al
    Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy().
    Leuk Lymphoma. 2022;63:928-938.
    PubMed     Abstract available

    March 2022
  101. KIERDORF F, Zimmer P, Joisten N, Kiesl D, et al
    L-kynurenine as a prognostic marker for early mortality in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2022 Mar 31:1-4. doi: 10.1080/10428194.2022.2053534.

  102. OCHS MA, Marini BL, Benitez LL, Stump SE, et al
    Multicenter comparison of first salvage chemotherapy versus novel therapy regimens in adult relapsed/refractory acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Mar 28:1-10. doi: 10.1080/10428194.2022.2053530.
    PubMed     Abstract available

  103. PERKINS B, Showel M, Schoch L, Imus PH, et al
    CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Mar 27:1-7. doi: 10.1080/10428194.2022.2038375.
    PubMed     Abstract available

  104. DEODATO M, Frustaci AM, Sportoletti P, Laurenti L, et al
    How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Mar 27:1-4. doi: 10.1080/10428194.2022.2053532.

  105. LIPTON NJ, Lipton JH
    Making the case for the case report - informing physicians of intracranial hypertension as an adverse event in tyrosine kinase inhibitor treated chronic myeloid leukemia patients.
    Leuk Lymphoma. 2022 Mar 25:1-2. doi: 10.1080/10428194.2022.2056180.

  106. GHOSH S, Roth J, Babushok D, Lim M, et al
    Significance of RUNX1 mutation in BCR-ABL1 positive acute myeloid leukemia - a diagnostic dilemma in a young woman with persistent bleeding.
    Leuk Lymphoma. 2022 Mar 15:1-5. doi: 10.1080/10428194.2022.2047673.

  107. GRAVENO ME, Carulli A, Freyer CW, Mangan BL, et al
    Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
    Leuk Lymphoma. 2022 Mar 8:1-6. doi: 10.1080/10428194.2022.2042688.
    PubMed     Abstract available

  108. TETTAMANTI S, Rotiroti MC, Giordano Attianese GMP, Arcangeli S, et al
    Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Mar 8:1-14. doi: 10.1080/10428194.2022.2043299.
    PubMed     Abstract available

  109. XIE W, Raess PW, Dunlap J, Hoyos CM, et al
    Adult acute myeloid leukemia patients with NUP98 rearrangement have frequent cryptic translocations and unfavorable outcome.
    Leuk Lymphoma. 2022 Mar 8:1-10. doi: 10.1080/10428194.2022.2047672.
    PubMed     Abstract available

  110. COLLARD JP, McKenna MK, Noothi SK, Alhakeem SS, et al
    Role of the splenic microenvironment in chronic lymphocytic leukemia development in Emicro-TCL1 transgenic mice.
    Leuk Lymphoma. 2022 Mar 8:1-13. doi: 10.1080/10428194.2022.2045596.
    PubMed     Abstract available

  111. ESHIBONA N, Giwa A, Rossouw SC, Gamieldien J, et al
    Upregulation of FHL1, SPNS3, and MPZL2 predicts poor prognosis in pediatric acute myeloid leukemia patients with FLT3-ITD mutation.
    Leuk Lymphoma. 2022 Mar 6:1-10. doi: 10.1080/10428194.2022.2045594.
    PubMed     Abstract available

  112. COLLINS J 4TH, Stump SE, Heiling H, Muir M, et al
    Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Mar 6:1-8. doi: 10.1080/10428194.2022.2045597.
    PubMed     Abstract available

  113. GUPTA DG, Varma N, Kumar A, Naseem S, et al
    PHi-RACE: PGIMER in-house rapid & cost effective classifier for the detection of BCR-ABL1-like acute lymphoblastic leukaemia in Indian patients.
    Leuk Lymphoma. 2022;63:633-643.
    PubMed     Abstract available

  114. BENDIG S, Stengel A, Walter W, Meggendorfer M, et al
    Diagnostic challenge of identifying cases with recurrent t(8;14)(q24.21;q32.2) Involving BCL11B in acute leukemias of ambiguous lineage: an analysis of eight patients.
    Leuk Lymphoma. 2022;63:747-750.

    February 2022
  115. FU W, Huang A, Xu L, Peng Y, et al
    Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia.
    Leuk Lymphoma. 2022 Feb 28:1-8. doi: 10.1080/10428194.2022.2045600.
    PubMed     Abstract available

  116. SIDDIQI T, Coutre S, McKinney M, Barr PM, et al
    Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
    Leuk Lymphoma. 2022 Feb 28:1-9. doi: 10.1080/10428194.2022.2038372.
    PubMed     Abstract available

  117. MUKHERJEE A, Milton DR, Jabbour EJ, Gulbis AM, et al
    Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.
    Leuk Lymphoma. 2022 Feb 27:1-9. doi: 10.1080/10428194.2022.2043302.
    PubMed     Abstract available

  118. MEHTA-SHAH N, Bartlett NL, Kahl B, Watkins MP, et al
    COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience.
    Leuk Lymphoma. 2022 Feb 27:1-5. doi: 10.1080/10428194.2022.2038377.

  119. VALDEZ BC, Yuan B, Murray D, Nieto Y, et al
    Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells.
    Leuk Lymphoma. 2022 Feb 20:1-11. doi: 10.1080/10428194.2022.2042689.
    PubMed     Abstract available

  120. KAUMEYER B, Fidai S, Sukhanova M, Yap KL, et al
    MUC4 expression by immunohistochemistry is a specific marker for BCR-ABL1+ and BCR-ABL1-like B-lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Feb 16:1-9. doi: 10.1080/10428194.2022.2025797.
    PubMed     Abstract available

  121. NAGAYAMA T, Fujiwara SI, Kikuchi T, Onda K, et al
    Impact of muscle mass loss assessed by computed tomography on the outcome of allogeneic stem cell transplantation.
    Leuk Lymphoma. 2022 Feb 14:1-7. doi: 10.1080/10428194.2022.2034159.
    PubMed     Abstract available

  122. KOCHNEVA CAPITAL O, CYRILLICL, Kislova M, Zhelnova EI, Petrenko AA, et al
    COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study.
    Leuk Lymphoma. 2022 Feb 13:1-10. doi: 10.1080/10428194.2022.2034157.
    PubMed     Abstract available

  123. AKHTAR OS, Groman A, Singh A, Ghione P, et al
    Frequency and timing of other primary cancers in patients with chronic lymphocytic leukemia (CLL): a 17-year longitudinal study.
    Leuk Lymphoma. 2022 Feb 13:1-10. doi: 10.1080/10428194.2021.2012662.
    PubMed     Abstract available

  124. FAZIO F, Cunsolo G, Mancini F, De Propris MS, et al
    Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Feb 8:1-3. doi: 10.1080/10428194.2022.2032035.

  125. YUAN Y, Li J, Xue TL, Hu HR, et al
    Prognostic significance of NOTCH1/FBXW7 mutations in pediatric T cell acute lymphoblastic leukemia: a study of minimal residual disease risk-directed CCLG-ALL 2008 treatment protocol.
    Leuk Lymphoma. 2022 Feb 6:1-10. doi: 10.1080/10428194.2022.2032033.
    PubMed     Abstract available

  126. SHALLIS RM, Gore SD
    Agent Orange and dioxin-induced myeloid leukemia: a weaponized vehicle of leukemogenesis.
    Leuk Lymphoma. 2022 Feb 2:1-10. doi: 10.1080/10428194.2022.2034156.
    PubMed     Abstract available

  127. RAMALINGAM TR, Mohanraj S, Muthu A, Prabhakar V, et al
    Independent diagnostic utility of CD20, CD200, CD43 and CD45 in chronic lymphocytic leukaemia.
    Leuk Lymphoma. 2022;63:377-384.
    PubMed     Abstract available

    January 2022
  128. ROY T, An JB, Doucette K, Chappell AM, et al
    Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression.
    Leuk Lymphoma. 2022 Jan 25:1-3. doi: 10.1080/10428194.2021.2010065.

  129. AMREIN P, Ballen K, Stevenson K, Brunner A, et al
    Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults.
    Leuk Lymphoma. 2022 Jan 25:1-8. doi: 10.1080/10428194.2021.2018582.
    PubMed     Abstract available

  130. CHAUDHARY S, Ganguly S, Singh A, Palanichamy JK, et al
    Mitochondrial biogenesis gene POLG correlates with outcome in pediatric acute myeloid leukemia.
    Leuk Lymphoma. 2022 Jan 25:1-4. doi: 10.1080/10428194.2021.2010063.

  131. WANG SSY
    Relationship between leukaemic stem cells and hematopoietic stem cells and their clinical application.
    Leuk Lymphoma. 2022 Jan 22:1-10. doi: 10.1080/10428194.2022.2027401.
    PubMed     Abstract available

  132. MELEN CM, Merrien M, Wasik AM, Panagiotidis G, et al
    Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Jan 17:1-11. doi: 10.1080/10428194.2021.2020776.
    PubMed     Abstract available

  133. BURGER JA, Robak T, Demirkan F, Bairey O, et al
    Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.
    Leuk Lymphoma. 2022 Jan 11:1-12. doi: 10.1080/10428194.2021.2020779.
    PubMed     Abstract available

  134. SASAKI K, Kantarjian H, Jabbour E
    Prediction for sustained deep molecular response for treatment-free remission.
    Leuk Lymphoma. 2022;63:5-6.

  135. WILSON NR, Bover L, Konopleva M, Han L, et al
    CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies.
    Leuk Lymphoma. 2022;63:19-30.
    PubMed     Abstract available

  136. HALPERN AB, Othus M, Howard NP, Hendrie PC, et al
    Comparative analysis of infectious complications with outpatient vs. inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy.
    Leuk Lymphoma. 2022;63:142-151.
    PubMed     Abstract available

  137. EL HUSSEIN S, Hu S, Fang H, Garces S, et al
    Well-differentiated systemic mastocytosis with associated myeloid sarcoma and myelodysplastic syndrome: Diagnostic challenges of an underrecognized entity.
    Leuk Lymphoma. 2022;63:235-238.

    December 2021
  138. MESSORI A, Rivano M, Mengato D, Cancanelli L, et al
    A preliminary estimate of survival gain and cost-effectiveness of CAR-T in adult patients with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Dec 31:1-4. doi: 10.1080/10428194.2021.2022141.

  139. ROBOZ GJ, Yee K, Verma A, Borthakur G, et al
    Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
    Leuk Lymphoma. 2021 Dec 19:1-5. doi: 10.1080/10428194.2021.2012667.

  140. MCQUILTEN ZK, Busija L, Seymour JF, Stanworth S, et al
    Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia.
    Leuk Lymphoma. 2021 Dec 17:1-8. doi: 10.1080/10428194.2021.2012664.
    PubMed     Abstract available

  141. HUNTINGTON SF, Ingham MP, Okonkwo L, Singh A, et al
    Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015-2020.
    Leuk Lymphoma. 2021 Dec 16:1-11. doi: 10.1080/10428194.2021.2012666.
    PubMed     Abstract available

  142. KANAGAL-SHAMANNA R, Bao H, Kearney H, Smoley S, et al
    Molecular characterization of Novel ATM fusions in chronic lymphocytic leukemia and T-cell prolymphocytic leukemia.
    Leuk Lymphoma. 2021 Dec 13:1-11. doi: 10.1080/10428194.2021.2010061.
    PubMed     Abstract available

  143. CABRERA ME, Marinov N, Roa M, Castillo JJ, et al
    Epidemiology of chronic lymphocytic leukemia in Chilean and Amerindian population in Chile.
    Leuk Lymphoma. 2021 Dec 10:1-7. doi: 10.1080/10428194.2021.2012663.
    PubMed     Abstract available

  144. SALHOTRA A, Yang D, Mokhtari S, Hui S, et al
    Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation.
    Leuk Lymphoma. 2021 Dec 9:1-7. doi: 10.1080/10428194.2021.2012661.
    PubMed     Abstract available

  145. SHEN X, Zhang L, Xing S, Zhang XW, et al
    Inhibition of pyrimidine biosynthesis by strobilurin derivatives induces differentiation of acute myeloid leukemia cells.
    Leuk Lymphoma. 2021 Dec 8:1-9. doi: 10.1080/10428194.2021.2008382.
    PubMed     Abstract available

  146. EGELI DB, Hanfstein B, Lauseker M, Pfirrmann M, et al
    SOCS-2 gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatment.
    Leuk Lymphoma. 2021 Dec 6:1-8. doi: 10.1080/10428194.2021.2010059.
    PubMed     Abstract available

  147. BANASZAK LG, Reinig E, Lasarev MR, Mattison RJ, et al
    Clinical utility and real-world application of molecular genetic sequencing in the management of patients with acute myeloid leukemia and myelodysplastic syndromes.
    Leuk Lymphoma. 2021 Dec 6:1-10. doi: 10.1080/10428194.2021.1999435.
    PubMed     Abstract available

  148. GAGEZ AL, Paul F, Alaterre E, Gouilleux-Gruart V, et al
    Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO study.
    Leuk Lymphoma. 2021;62:3160-3169.
    PubMed     Abstract available

  149. BEWERSDORF JP, Stone RM, Tallman MS, Stahl M, et al
    Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?
    Leuk Lymphoma. 2021;62:3318-3319.

  150. BEWERSDORF JP, Derkach A, Gowda L, Menghrajani K, et al
    Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant.
    Leuk Lymphoma. 2021;62:3394-3401.
    PubMed     Abstract available

  151. SMALL SH, Altman JK, Platanias LC
    Interferon maintenance for prevention of relapse in favorable risk AML?
    Leuk Lymphoma. 2021;62:2818-2819.

  152. STABER PB, Jurczak W, Greil R, Vucinic V, et al
    Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
    Leuk Lymphoma. 2021;62:3440-3451.
    PubMed     Abstract available

  153. LUKES J, Wolthers BO, Altaf Raja R, Uhrinova K, et al
    Pancreatitis-associated protein as an early marker of asparaginase-associated pancreatitis.
    Leuk Lymphoma. 2021;62:3506-3510.

  154. LU H, Li ZY, Ding M, Liang C, et al
    Trametinib enhances ATRA-induced differentiation in AML cells.
    Leuk Lymphoma. 2021;62:3361-3372.
    PubMed     Abstract available

  155. LOO S, Wei AH
    Post-transplant maintenance therapy for MDS and AML: a bridge too far or the beginning of a new era?
    Leuk Lymphoma. 2021;62:3073-3077.

  156. WAGNER-JOHNSTON ND, Sharman J, Furman RR, Salles G, et al
    Idelalisib immune-related toxicity is associated with improved treatment response.
    Leuk Lymphoma. 2021;62:2915-2920.
    PubMed     Abstract available

  157. MEGHEREA O, Janes C, Kowalski A, Baron J, et al
    Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome.
    Leuk Lymphoma. 2021;62:3219-3225.
    PubMed     Abstract available

  158. SHIMONY S, Bar-Sever E, Berger T, Itchaki G, et al
    Late onset neutropenia after rituximab and obinutuzumab treatment - characteristics of a class-effect toxicity.
    Leuk Lymphoma. 2021;62:2921-2927.
    PubMed     Abstract available

    November 2021
  159. PRZESPOLEWSKI AC, Portwood S, Wang ES
    Targeting acute myeloid leukemia through multimodal immunotherapeutic approaches.
    Leuk Lymphoma. 2021 Nov 25:1-10. doi: 10.1080/10428194.2021.1992614.
    PubMed     Abstract available

  160. PALMIERI R, Buccisano F, Arena V, Irno Consalvo MA, et al
    CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia.
    Leuk Lymphoma. 2021 Nov 21:1-5. doi: 10.1080/10428194.2021.2005042.

  161. KHANAL N, Shostrom V, Dhakal P, Upadhyay Banskota S, et al
    Determinants of ten-year overall survival of acute myeloid leukemia: a large national cancer database analysis.
    Leuk Lymphoma. 2021 Nov 17:1-7. doi: 10.1080/10428194.2021.2005046.
    PubMed     Abstract available

  162. YUE X, Hincapie AL, Li Y, Guo JJ, et al
    Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States.
    Leuk Lymphoma. 2021 Nov 15:1-9. doi: 10.1080/10428194.2021.2002320.
    PubMed     Abstract available

  163. JADERSTEN M, Boriskina K, Lindholm C, Westrom S, et al
    Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation.
    Leuk Lymphoma. 2021 Nov 15:1-4. doi: 10.1080/10428194.2021.2002319.

  164. HALPERN AB, Estey EH
    More general incorporation of hemoglobin level into response criteria for myelodysplastic syndrome and acute myeloid leukemia with increase in minimum red cell transfusion levels.
    Leuk Lymphoma. 2021 Nov 8:1-4. doi: 10.1080/10428194.2021.1999446.

  165. ZEIDAN AM, Qi CZ, Yang H, Garnham A, et al
    Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial.
    Leuk Lymphoma. 2021 Nov 8:1-3. doi: 10.1080/10428194.2021.2001467.

  166. DA CUNHA-BANG C, Kirkby NS, Friis-Hansen L, Niemann CU, et al
    Serological response following vaccination with BNT162b2 mRNA in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Nov 2:1-3. doi: 10.1080/10428194.2021.1973673.

  167. ARUMUGAM JR, Bommannan K, Radhakrishnan V, Sagar TG, et al
    Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry.
    Leuk Lymphoma. 2021 Nov 2:1-9. doi: 10.1080/10428194.2021.1992755.
    PubMed     Abstract available

  168. RIDGE SM, Whiteley AE, Yao H, Price TT, et al
    Pan-PI3Ki targets multiple B-ALL microenvironment interactions that fuel systemic and CNS relapse.
    Leuk Lymphoma. 2021;62:2690-2702.
    PubMed     Abstract available

  169. SOARE DS, Radu E, Dumitru I, Vladareanu AM, et al
    Quantitative analyses of CD7, CD33, CD34, CD56, and CD123 within the FLT3-ITD/NPM1-MUT myeloblastic/monocytic bulk AML blastic populations.
    Leuk Lymphoma. 2021;62:2716-2726.
    PubMed     Abstract available

  170. PATNAIK MM, Mughal TI, Brooks C, Lindsay R, et al
    Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy.
    Leuk Lymphoma. 2021;62:2568-2586.
    PubMed     Abstract available

    October 2021
  171. ALDOSS I, Clark M, Marcucci G, Forman SJ, et al
    Donor derived leukemia in allogeneic transplantation.
    Leuk Lymphoma. 2021 Oct 29:1-8. doi: 10.1080/10428194.2021.1929966.
    PubMed     Abstract available

  172. REX MR, Williams R, Birsoy K, Ta Llman MS, et al
    Targeting mitochondrial metabolism in acute myeloid leukemia.
    Leuk Lymphoma. 2021 Oct 27:1-8. doi: 10.1080/10428194.2021.1992759.
    PubMed     Abstract available

  173. GHIUZELI CM, Styblo M, Saunders J, Calabro A, et al
    The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients.
    Leuk Lymphoma. 2021 Oct 25:1-11. doi: 10.1080/10428194.2021.1978084.
    PubMed     Abstract available

  174. TONG WH
    Comment on 'asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly diagnosed acute lymphoblastic leukemia'.
    Leuk Lymphoma. 2021 Oct 22:1-2. doi: 10.1080/10428194.2021.1992760.

  175. CHEN M, Fu M, Wang A, Wu X, et al
    Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy.
    Leuk Lymphoma. 2021 Oct 21:1-9. doi: 10.1080/10428194.2021.1980214.
    PubMed     Abstract available

  176. GJAERDE LK, Rank CU, Andersen MK, Jakobsen LH, et al
    Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study.
    Leuk Lymphoma. 2021 Oct 21:1-10. doi: 10.1080/10428194.2021.1992620.
    PubMed     Abstract available

  177. RAMOS PEREZ JM, Patel KP, Loghavi S, Garcia-Manero G, et al
    Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy.
    Leuk Lymphoma. 2021 Oct 20:1-4. doi: 10.1080/10428194.2021.1992757.
    PubMed     Abstract available

  178. DOMENECH C, Plesa A, Tourette A, Bertrand Y, et al
    Prognostic impact of cN-III mRNA expression on overall survival and drug sensitivity in pediatric leukemia.
    Leuk Lymphoma. 2021 Oct 18:1-6. doi: 10.1080/10428194.2021.1992616.

  179. LI S, Ji Y, Peng Y, Kota V, et al
    Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with acute myeloid leukemia meeting ineligibility criteria for high intensity chemotherapy.
    Leuk Lymphoma. 2021 Oct 13:1-11. doi: 10.1080/10428194.2021.1973669.
    PubMed     Abstract available

  180. COCHRANE T, Enrico A, Gomez-Almaguer D, Hadjiev E, et al
    Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial.
    Leuk Lymphoma. 2021 Oct 11:1-11. doi: 10.1080/10428194.2021.1986217.
    PubMed     Abstract available

  181. AGIUS R, Parviz M, Niemann CU
    Artificial intelligence models in chronic lymphocytic leukemia - recommendations toward state-of-the-art.
    Leuk Lymphoma. 2021 Oct 6:1-14. doi: 10.1080/10428194.2021.1973672.
    PubMed     Abstract available

  182. XUE S, Zhang Y, Liu F, Huang W, et al
    Olaparib combined with chemotherapy for treatment of T-cell acute lymphoblastic leukemia relapse after unrelated umbilical cord blood transplantation.
    Leuk Lymphoma. 2021 Oct 5:1-5. doi: 10.1080/10428194.2021.1984453.

  183. NACHMIAS B, Rund D
    p53 in Acute Myeloid Leukemia-Still a significant other.
    Leuk Lymphoma. 2021 Oct 5:1-3. doi: 10.1080/10428194.2021.1988592.

  184. LEE Y, Yun J, Jeong D, Ryu S, et al
    Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma.
    Leuk Lymphoma. 2021 Oct 1:1-10. doi: 10.1080/10428194.2021.1983568.
    PubMed     Abstract available

    The tools to choose: applying indirect treatment comparisons to the selection of frontline targeted therapy for CLL.
    Leuk Lymphoma. 2021;62:2299-2302.

  186. ALHALLAK K, de la Puente P, Jeske A, Sun J, et al
    3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance.
    Leuk Lymphoma. 2021;62:2457-2465.
    PubMed     Abstract available

  187. JACOBY MA, Finn L, Emadi A, Saba NS, et al
    Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC).
    Leuk Lymphoma. 2021;62:2539-2542.

  188. RAMAN I, Pasricha SR, Prince HM, Yannakou CK, et al
    Management of hydroxyurea resistant or intolerant polycythemia vera.
    Leuk Lymphoma. 2021;62:2310-2319.
    PubMed     Abstract available

  189. SHIMONY S, Yeshurun M, Wolach O, Ram R, et al
    Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients - a multicenter retrospective observational study.
    Leuk Lymphoma. 2021;62:2475-2481.
    PubMed     Abstract available

    September 2021
  190. VAN BESIEN K, Gomez-Arteaga A
    Maintenance therapy after allogeneic transplant for acute myeloid leukemia: great expectations.
    Leuk Lymphoma. 2021 Sep 29:1-4. doi: 10.1080/10428194.2021.1980787.

  191. MALPICA L, Castro D, Enriquez DJ, Oviedo-Pecho R, et al
    An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2021 Sep 29:1-11. doi: 10.1080/10428194.2021.1984455.
    PubMed     Abstract available

  192. CHAJUWAN T, Kansuwan P, Kobbuaklee S, Chanswangphuwana C, et al
    Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2021 Sep 29:1-7. doi: 10.1080/10428194.2021.1984454.
    PubMed     Abstract available

  193. ALDERUCCIO JP, Lossos IS
    NOTCH signaling in the pathogenesis of splenic marginal zone lymphoma-opportunities for therapy.
    Leuk Lymphoma. 2021 Sep 29:1-12. doi: 10.1080/10428194.2021.1984452.
    PubMed     Abstract available

  194. STAHL M, Tallman MS, Goldberg AD
    Measurable residual disease negativity in acute myeloid leukemia: the destination may matter more than the journey.
    Leuk Lymphoma. 2021 Sep 14:1-2. doi: 10.1080/10428194.2021.1929967.

  195. PATEL SA, Lloyd MR, Cerny J, Shi Q, et al
    Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia.
    Leuk Lymphoma. 2021 Sep 9:1-13. doi: 10.1080/10428194.2021.1957869.
    PubMed     Abstract available

  196. BANKAR A, Lipton JH
    Association of creatine kinase elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study.
    Leuk Lymphoma. 2021 Sep 8:1-10. doi: 10.1080/10428194.2021.1971219.
    PubMed     Abstract available

  197. KHULLAR K, Plascak JJ, Parikh RR
    Acute lymphoblastic leukemia (ALL) in adults: disparities in treatment intervention based on access to treatment facility.
    Leuk Lymphoma. 2021 Sep 8:1-9. doi: 10.1080/10428194.2021.1975187.
    PubMed     Abstract available

  198. JACOBS JW, Ramaswamy R, States V, Reppucci J, et al
    Chronic myeloid leukemia with pure erythroid leukemia blast crisis.
    Leuk Lymphoma. 2021 Sep 6:1-5. doi: 10.1080/10428194.2021.1975191.
    PubMed     Abstract available

  199. XU DM, Yu WJ, Xie L, Zhang ZW, et al
    The diagnostic profile of rare acute myelomegakaryoblastic leukemia.
    Leuk Lymphoma. 2021 Sep 3:1-8. doi: 10.1080/10428194.2021.1955878.
    PubMed     Abstract available

  200. VENUGOPAL S, Maiti A, DiNardo CD, Qiao W, et al
    Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.
    Leuk Lymphoma. 2021 Sep 3:1-5. doi: 10.1080/10428194.2021.1973675.

  201. DUPUY H, Dussiau C, Bidet A, Sauvezie M, et al
    Looking for somatic mutations in UBA1 in patients with chronic myelomonocytic leukemia associated with systemic inflammation and autoimmune diseases.
    Leuk Lymphoma. 2021 Sep 3:1-3. doi: 10.1080/10428194.2021.1973674.

    August 2021
  202. HANSENNE A, Camboni A, Van Den Neste E, Bailly S, et al
    Richter transformation heralded by EBV reactivation during ibrutinib therapy for chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Aug 25:1-3. doi: 10.1080/10428194.2021.1964023.

  203. PATEL SA, Dalela D, Fan AC, Lloyd MR, et al
    Niche-directed therapy in acute myeloid leukemia: optimization of stem cell competition for niche occupancy.
    Leuk Lymphoma. 2021 Aug 19:1-9. doi: 10.1080/10428194.2021.1966779.
    PubMed     Abstract available

  204. ZERBIT J, Tamburini J, Goldwirt L, Decroocq J, et al
    Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Aug 18:1-4. doi: 10.1080/10428194.2021.1966787.

  205. WANG J, Yang L, Dao FT, Wang YZ, et al
    Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8;21) acute myeloid leukemia.
    Leuk Lymphoma. 2021 Aug 18:1-10. doi: 10.1080/10428194.2021.1966785.
    PubMed     Abstract available

  206. KIMBLE EL, Cassaday RD
    Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults.
    Leuk Lymphoma. 2021 Aug 17:1-15. doi: 10.1080/10428194.2021.1964022.
    PubMed     Abstract available

  207. SOREL N, Raimbault A, Brizard F, Depaire T, et al
    Identification and genetic characterization of a NUP98-HHEX molecular rearrangement in a pediatric acute myeloid leukemia.
    Leuk Lymphoma. 2021 Aug 17:1-5. doi: 10.1080/10428194.2021.1966784.

  208. MITROVIC M, Pantic N, Sabljic N, Vucic M, et al
    Acute leukemia and SARS-CoV-2 infection: clinical characteristics and risk factors for mortality.
    Leuk Lymphoma. 2021 Aug 13:1-5. doi: 10.1080/10428194.2021.1964026.
    PubMed     Abstract available

  209. WOYACH J, Tedeschi A, Munir T, Siddiqi T, et al
    Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2021 Aug 13:1-5. doi: 10.1080/10428194.2021.1957871.

  210. ABBAS HA, Reville PK, Geppner A, Rausch CR, et al
    Clinical and molecular characterization of myeloid sarcoma without medullary leukemia.
    Leuk Lymphoma. 2021 Aug 12:1-9. doi: 10.1080/10428194.2021.1961235.
    PubMed     Abstract available

  211. NEE A, Lipton JH, Kim DDH
    Early prediction of stable MR(4.5) by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinib.
    Leuk Lymphoma. 2021 Aug 11:1-8. doi: 10.1080/10428194.2021.1961234.
    PubMed     Abstract available

  212. CORDOVA-SERRANO RD, Almanza-Huante E, Fernandez-Sanchez E, Hernandez-Alcantara A, et al
    Central nervous system (CNS) involvement has an adverse impact on survival in newly diagnosed adult acute lymphoblastic leukemia (ALL) assessed by flow cytometry.
    Leuk Lymphoma. 2021 Aug 9:1-7. doi: 10.1080/10428194.2021.1957872.
    PubMed     Abstract available

  213. KUTTIKRISHNAN S, Prabhu KS, Khan AQ, Alali FQ, et al
    Thiostrepton inhibits growth and induces apoptosis by targeting FoxM1/SKP2/MTH1 axis in B-precursor acute lymphoblastic leukemia cells.
    Leuk Lymphoma. 2021 Aug 9:1-11. doi: 10.1080/10428194.2021.1957873.
    PubMed     Abstract available

  214. AL-HADAD SA, Al-Jadiry MF, Ghali HH, Al-Badri SAF, et al
    Treatment of childhood acute lymphoblastic leukemia in Iraq: a 17-year experience from a single center.
    Leuk Lymphoma. 2021 Aug 6:1-10. doi: 10.1080/10428194.2021.1961237.
    PubMed     Abstract available

  215. YANADA M, Mizuno S, Yamasaki S, Harada K, et al
    Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes.
    Leuk Lymphoma. 2021 Aug 4:1-9. doi: 10.1080/10428194.2021.1961242.
    PubMed     Abstract available

  216. COPPOLA PE, Broccoli A, Argnani L, Casadei B, et al
    Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases.
    Leuk Lymphoma. 2021 Aug 4:1-4. doi: 10.1080/10428194.2021.1961241.

  217. RAMIREZ-LOPEZ A, Lazaro Del Campo P, Humala K, De la Cruz Benito B, et al
    Lessons learned for successful treatment of AML in the second wave of COVID-19 outbreak.
    Leuk Lymphoma. 2021;62:2034-2036.

  218. ROSSO A, Juliusson G, Lorenz F, Lehmann S, et al
    Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study.
    Leuk Lymphoma. 2021;62:1973-1981.
    PubMed     Abstract available

  219. NAUR TMH, Jakobsen LH, Roug AS, El-Galaly TC, et al
    Treatment intensity and survival trends among real-world elderly AML patients diagnosed in the period 2001-2016: a Danish nationwide cohort study.
    Leuk Lymphoma. 2021;62:2014-2017.

    July 2021
  220. WAN CL, Zou JY, Qiao M, Yin J, et al
    Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series.
    Leuk Lymphoma. 2021 Jul 29:1-4. doi: 10.1080/10428194.2021.1957876.

  221. KOUTROUMANI M, Laidou S, Kotta K, Stamatopoulos K, et al
    TAp63 and BCL2 expression are co-affected by cell-extrinsic signals in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Jul 29:1-4. doi: 10.1080/10428194.2021.1957870.

  222. SWEET K, Bhatnagar B, Dohner H, Donnellan W, et al
    A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2021 Jul 29:1-12. doi: 10.1080/10428194.2021.1950706.
    PubMed     Abstract available

  223. EL HUSSEIN S, Wang W, Wang SA, Loghavi S, et al
    Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenomenon.
    Leuk Lymphoma. 2021 Jul 24:1-4. doi: 10.1080/10428194.2021.1957878.

  224. PALANQUES-PASTOR T, Megias-Vericat JE, Martinez P, Lopez Lorenzo JL, et al
    Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group.
    Leuk Lymphoma. 2021 Jul 22:1-11. doi: 10.1080/10428194.2021.1948031.
    PubMed     Abstract available

  225. WEBSTER JA, Yogarajah M, Zahurak M, Symons H, et al
    A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic
    Leuk Lymphoma. 2021 Jul 21:1-11. doi: 10.1080/10428194.2021.1948029.
    PubMed     Abstract available

  226. DUNN KA, Forbrigger Z, Connors J, Rahman M, et al
    Gut bacterial gene changes following pegaspargase treatment in pediatric patients with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Jul 19:1-12. doi: 10.1080/10428194.2021.1953006.
    PubMed     Abstract available

  227. BEYAN C
    Mean platelet volume may not be a predictive and prognostic marker in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2021 Jul 14:1. doi: 10.1080/10428194.2021.1953017.

  228. GAO J, Fu L, Lu X, Sukhanova M, et al
    Mast cell sarcoma transdifferentiated from clonally-related T-lymphoblastic leukemia upon acquisition of TP53 mutation and genetic complexity.
    Leuk Lymphoma. 2021 Jul 14:1-4. doi: 10.1080/10428194.2021.1950710.

  229. PAGNANO KB, Peralta EH, Navarro JR, David Salas LDR, et al
    COVID-19 in chronic myeloid leukemia patients in Latin America.
    Leuk Lymphoma. 2021 Jul 13:1-7. doi: 10.1080/10428194.2021.1950709.
    PubMed     Abstract available

  230. JIANG H, Liu XH, Kong J, Wang J, et al
    Interferon-alpha as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia.
    Leuk Lymphoma. 2021 Jul 1:1-8. doi: 10.1080/10428194.2021.1948027.
    PubMed     Abstract available

  231. JINDAL N, Lad DP, Malhotra P, Prakash G, et al
    Randomized controlled trial of individualized, low dose, fixed duration lenalidomide maintenance versus observation after frontline chemo-immunotherapy in CLL.
    Leuk Lymphoma. 2021;62:1674-1681.
    PubMed     Abstract available

  232. WITTMANN DAYAGI T, Sherman G, Bielorai B, Adam E, et al
    Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells.
    Leuk Lymphoma. 2021;62:1692-1701.
    PubMed     Abstract available

    June 2021
  233. STAHL M, Narendra V, Jee J, Derkach A, et al
    Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality.
    Leuk Lymphoma. 2021 Jun 28:1-9. doi: 10.1080/10428194.2021.1885664.
    PubMed     Abstract available

  234. LEPRETRE S, Touboul C, Flinois A, Kutikova L, et al
    Quality of life in adults with acute lymphoblastic leukemia in France: results from a French cross-sectional study.
    Leuk Lymphoma. 2021 Jun 24:1-11. doi: 10.1080/10428194.2021.1941924.
    PubMed     Abstract available

  235. YOSHIMOTO G, Mori Y, Kato K, Odawara J, et al
    Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation.
    Leuk Lymphoma. 2021 Jun 23:1-10. doi: 10.1080/10428194.2021.1941937.
    PubMed     Abstract available

  236. SINGH J, Facey A, O'Malley F, Ryland GL, et al
    Cryptic molecular lesion in acute promyelocytic leukemia with negative initial FISH.
    Leuk Lymphoma. 2021 Jun 21:1-3. doi: 10.1080/10428194.2021.1941935.

  237. HADJIAGGELIDOU C, Douganiotis G, Tsirou K, Verrou E, et al
    A rare case of autoimmune hemolytic anemia during venetoclax therapy for relapsed chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Jun 21:1-3. doi: 10.1080/10428194.2021.1941932.

  238. RAMKISSOON LA, Buhlinger K, Nichols A, Coombs CC, et al
    Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after enasidenib treatment.
    Leuk Lymphoma. 2021 Jun 21:1-4. doi: 10.1080/10428194.2021.1941928.

  239. BOLUDA B, Martinez-Cuadron D, Algarra L, Cano I, et al
    Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.
    Leuk Lymphoma. 2021 Jun 14:1-10. doi: 10.1080/10428194.2021.1938031.
    PubMed     Abstract available

  240. CHIHARA D, Larson MC, Robinson DP, Thompson CA, et al
    Body mass index and survival of patients with lymphoma.
    Leuk Lymphoma. 2021 Jun 14:1-8. doi: 10.1080/10428194.2021.1929956.
    PubMed     Abstract available

  241. KHAZAL S, Kebriaei P
    Hematopoietic cell transplantation for acute lymphoblastic leukemia: review of current indications and outcomes.
    Leuk Lymphoma. 2021 Jun 3:1-14. doi: 10.1080/10428194.2021.1933475.
    PubMed     Abstract available

  242. STUBBINS RJ, Maksakov IA, Sanford DS, Rouhi A, et al
    Mitochondrial metabolism: powering new directions in acute myeloid leukemia.
    Leuk Lymphoma. 2021 Jun 1:1-11. doi: 10.1080/10428194.2021.1910685.
    PubMed     Abstract available

  243. BOULLAND ML, Vic S, Thonier F, Ganard M, et al
    Reliable IGHV status assessment by next generation sequencing in routine practice for chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Jun 1:1-4. doi: 10.1080/10428194.2021.1933476.

  244. LADHA A, Hui G, Cheung E, Berube C, et al
    Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML.
    Leuk Lymphoma. 2021;62:1510-1513.

  245. SENAPATI J, Dhawan R, Aggarwal M, Kumar P, et al
    Venetoclax and azacitidine (VenAZA) combination therapy in young unfit patients with AML: a perspective from a developing country.
    Leuk Lymphoma. 2021;62:1514-1517.

  246. QU S, Jia Y, Wang H, Ai X, et al
    STAT3 and STAT5B mutations have unique distribution in T-cell large granular lymphocyte proliferations and advanced myeloid neoplasms.
    Leuk Lymphoma. 2021;62:1506-1509.

    May 2021
  247. YURKIEWICZ IR, Coutre S, Ghesquieres H, Pastan I, et al
    Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia.
    Leuk Lymphoma. 2021 May 25:1-3. doi: 10.1080/10428194.2021.1929959.

  248. CUMBO C, Tota G, De Grassi A, Anelli L, et al
    RUNX1 gene alterations characterized by allelic preference in adult acute myeloid leukemia.
    Leuk Lymphoma. 2021 May 24:1-5. doi: 10.1080/10428194.2021.1929960.

  249. SHARMA P, Rana S, Virk H, Sachdeva MUS, et al
    The frequency, hematological characteristics, and end-of induction residual disease in B-acute lymphoblastic leukemia with BCR-ABL1-like chimeric gene fusions in a high-risk cohort from India.
    Leuk Lymphoma. 2021 May 24:1-5. doi: 10.1080/10428194.2021.1929964.

  250. JIN H, Zhu Y, Hong M, Wu Y, et al
    Co-occurrence of KIT and NRAS mutations defines an adverse prognostic core-binding factor acute myeloid leukemia.
    Leuk Lymphoma. 2021 May 24:1-10. doi: 10.1080/10428194.2021.1919660.
    PubMed     Abstract available

  251. BAZINET A, Rys RN, Barry A, Greenwood CMT, et al
    A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 May 21:1-8. doi: 10.1080/10428194.2021.1919658.
    PubMed     Abstract available

  252. TIGLIOGLU M, Albayrak M, Dogan S, Yilmaz F, et al
    Mean platelet volume is a predictive and prognostic marker for patients with acute myeloid leukemia: a two-center retrospective analysis.
    Leuk Lymphoma. 2021 May 20:1-7. doi: 10.1080/10428194.2021.1929962.
    PubMed     Abstract available

  253. HANDL S, von Heydebrand F, Voelkl S, Oostendorp RAJ, et al
    Immune modulatory effects of Idelalisib in stromal cells of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 May 17:1-11. doi: 10.1080/10428194.2021.1927019.
    PubMed     Abstract available

  254. LIANG D, Wei C, Zhang X, Yang J, et al
    Efficacy of lenalidomide for relapsed or refractory T lymphoblastic lymphoma/leukemia after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2021 May 17:1-5. doi: 10.1080/10428194.2021.1919665.

  255. KUROSAWA S, Kaito S, Uchida N, Fukuda T, et al
    Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia with high hyperdiploidy: a retrospective nationwide study.
    Leuk Lymphoma. 2021 May 12:1-7. doi: 10.1080/10428194.2021.1924374.
    PubMed     Abstract available

  256. DAVIDS MS, Telford C, Abhyankar S, Waweru C, et al
    Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naive chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 May 6:1-16. doi: 10.1080/10428194.2021.1913144.
    PubMed     Abstract available

  257. ADNAN-AWAD S, Kankainen M, Mustjoki S
    Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia.
    Leuk Lymphoma. 2021 May 4:1-15. doi: 10.1080/10428194.2021.1894652.
    PubMed     Abstract available

  258. MARQUES-PIUBELLI ML, Schlette EJ, Khoury JD, Furqan F, et al
    Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax.
    Leuk Lymphoma. 2021;62:1129-1135.
    PubMed     Abstract available

    April 2021
  259. WALLWITZ J, Aigner P, Stoiber D
    Tumor suppressors in acute myeloid leukemia.
    Leuk Lymphoma. 2021 Apr 30:1-11. doi: 10.1080/10428194.2021.1907372.
    PubMed     Abstract available

  260. WANG M, Wang R, Wang H, Chen C, et al
    Difference in gene mutation profile in patients with refractory/relapsed versus newly diagnosed acute myeloid leukemia based on targeted next-generation sequencing.
    Leuk Lymphoma. 2021 Apr 29:1-12. doi: 10.1080/10428194.2021.1919661.
    PubMed     Abstract available

  261. WANG N, Yuan L, Jing Y, Fan K, et al
    Double minute chromosomes in acute myeloid leukemia and myelodysplastic syndromes are associated with complex karyotype, monosomal karyotype, TP53 deletion, and TP53 mutations.
    Leuk Lymphoma. 2021 Apr 27:1-9. doi: 10.1080/10428194.2021.1919663.
    PubMed     Abstract available

  262. REES MJ, Wu S, Mokoonlall M, Dix CHK, et al
    The real-world tolerability and efficacy of asparaginase in adults aged 40 years and older with Philadelphia-negative acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Apr 26:1-3. doi: 10.1080/10428194.2021.1919666.

  263. ZHAN M, Chen ZB, Ding CC, Qu Q, et al
    Machine learning to predict high-dose methotrexate-related neutropenia and fever in children with B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Apr 26:1-12. doi: 10.1080/10428194.2021.1913140.
    PubMed     Abstract available

  264. GUPTA A, Gill S
    CAR-T cell persistence in the treatment of leukemia and lymphoma.
    Leuk Lymphoma. 2021 Apr 19:1-13. doi: 10.1080/10428194.2021.1913146.
    PubMed     Abstract available

  265. WALKER KL, Rinella SP, Hess NJ, Turicek DP, et al
    CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration.
    Leuk Lymphoma. 2021 Apr 11:1-11. doi: 10.1080/10428194.2021.1910684.
    PubMed     Abstract available

  266. FAZIO F, Quintini M, Carmosino I, Matteucci C, et al
    New dead/H-box helicase gene (ddx41) mutation in an Italian family with recurrent leukemia.
    Leuk Lymphoma. 2021 Apr 9:1-4. doi: 10.1080/10428194.2021.1910689.

  267. BENITEZ LL, Perissinotti AJ, Rausch CR, Klaus J, et al
    Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia.
    Leuk Lymphoma. 2021 Apr 8:1-9. doi: 10.1080/10428194.2021.1907378.
    PubMed     Abstract available

  268. PASIC I, Paulson K, Dozois G, Schultz KR, et al
    Inferior outcomes with reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation in fit individuals with acute lymphoblastic leukemia: a Canadian single-center study and a comparison to registry data.
    Leuk Lymphoma. 2021 Apr 8:1-9. doi: 10.1080/10428194.2021.1910688.
    PubMed     Abstract available

  269. HIDALGO-GOMEZ G, Palacio-Garcia C, Gallur L, Blanco A, et al
    Is acute lymphoblastic leukemia with mature B-cell phenotype and KMT2A rearrangements a new entity? A systematic review and meta-analysis.
    Leuk Lymphoma. 2021 Apr 7:1-9. doi: 10.1080/10428194.2021.1907375.
    PubMed     Abstract available

  270. JOBSON D, McCormack CJ, Hiscutt E, Tam C, et al
    Severe treatment-resistant autoimmune haemolytic anaemia following ipilimumab in a patient with metastatic melanoma and CLL.
    Leuk Lymphoma. 2021;62:992-994.

  271. HARROP S, Polliack A, Tam CS
    Chronic lymphoproliferative disorders and secondary cancers in the era of purine analogues and beyond.
    Leuk Lymphoma. 2021;62:771-778.
    PubMed     Abstract available

  272. PACOUREAU L, De Menthon M, Boytchev I, Lazure T, et al
    Severe ulcerative gastrointestinal toxicity following ibrutinib therapy: two case studies.
    Leuk Lymphoma. 2021;62:984-987.

    March 2021
  273. CHEN NC, Borthakur G, Pemmaraju N
    Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms.
    Leuk Lymphoma. 2021;62:528-537.
    PubMed     Abstract available

    December 2020
  274. FOX TA, Carpenter B, Taj M, Perisoglou M, et al
    Utility of 18F-FDG-PET/CT in lymphoblastic lymphoma.
    Leuk Lymphoma. 2020 Dec 4:1-6. doi: 10.1080/10428194.2020.1855346.

    November 2020
  275. RASOR B, Dickerson T, Zhao Q, Elder P, et al
    Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS.
    Leuk Lymphoma. 2020 Nov 24:1-10. doi: 10.1080/10428194.2020.1849677.
    PubMed     Abstract available

  276. WANG T, Zhou B, Zhang J, Zhang X, et al
    Allogeneic hematopoietic stem cell transplantation could improve survival for pure CBF-AML patients with minimal residual disease positive after the second consolidation.
    Leuk Lymphoma. 2020 Nov 16:1-4. doi: 10.1080/10428194.2020.1846736.
    PubMed     Abstract available

  277. PAN W, Zhao X, Shi W, Jiang Z, et al
    Venetoclax induced complete remission in extramedullary relapse of AML co-harboring NPM1, TET2, and NRAS mutations after haploidentical hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2020;61:2756-2759.

    October 2020
  278. RODGERS TD, Williams AM, Baran A, Reagan PM, et al
    Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Oct 25:1-8. doi: 10.1080/10428194.2020.1837796.
    PubMed     Abstract available

    August 2020
  279. NAGAHATA Y, Kondo T, Ono Y, Hiramoto N, et al
    High-dose cytarabine chemotherapy (>/=4 g/m(2)/day) before allogeneic hematopoietic stem cell transplantation for non-core-binding-factor AML in the first complete remission.
    Leuk Lymphoma. 2020 Aug 17:1-9. doi: 10.1080/10428194.2020.1805112.
    PubMed     Abstract available

    June 2020
  280. LU JP, Wang FX, Wen SP, Liu X, et al
    Haploidentical hematopoietic stem cell transplantation with 'Beijing protocol' in the treatment of T-lymphoblastic lymphoma.
    Leuk Lymphoma. 2020 Jun 16:1-4. doi: 10.1080/10428194.2020.1775205.

    January 2020
  281. RYLAND GL, Fox LC, Wootton V, Thompson ER, et al
    Severe chemotherapy toxicity in a 10-year-old with T-acute lymphoblastic lymphoma harboring biallelic FANCM variants.
    Leuk Lymphoma. 2020 Jan 16:1-3. doi: 10.1080/10428194.2019.1711075.

    October 2019
  282. KUMAR P, Uppal M, Xiao W, Dogan A, et al
    Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications.
    Leuk Lymphoma. 2019 Oct 15:1-5. doi: 10.1080/10428194.2019.1675876.

    September 2019
  283. WANG F, Liu T, Wang L, Gu Z, et al
    Unmanipulated haploidentical peripheral blood stem cell transplantation for patients with Philadelphia-negative acute lymphoblastic leukaemia in first complete remission.
    Leuk Lymphoma. 2019 Sep 13:1-10. doi: 10.1080/10428194.2019.1660965.
    PubMed     Abstract available

    August 2019
  284. BALDUCCI E, Sanekli S, Hugues P, Soubeyrand M, et al
    Co-occurrence of BCR-ABL1 rearrangement and CALR mutation in a single leukemic stem cell: evidence that BCR-ABL1 oncogenic addiction prevails over CALR signaling.
    Leuk Lymphoma. 2019 Aug 29:1-4. doi: 10.1080/10428194.2019.1658101.

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.